Expertise in
3
conditions

Dr. Everett Ribakove

Hematology
Southeastern Regional Medical Center
1200 Pine Run Dr, 
Lumberton, NC 
Offers Telehealth
Expertise in
3
conditions
Southeastern Regional Medical Center
1200 Pine Run Dr, 
Lumberton, NC 

Overview

Everett Ribakove is a Hematologist in Lumberton, North Carolina. Dr. Ribakove is highly rated in 3 conditions, according to our data. His top areas of expertise are Chronic Myelomonocytic Leukemia (CMML), Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, and Lung Cancer.

His clinical research consists of participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in NC

Hospital Affiliations

Unc Hospitals
Southeastern Regional Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Southeastern Regional Medical Center
1200 Pine Run Dr, Lumberton, NC 28358
Other Locations
Blueridge Physicians Group PLLC
724 Thomas St, Asheboro, NC 27203

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 6 Less Clinical Trials
Similar Doctors
Expertise in
8
conditions
Dr. Jane Little
Hematology
Expertise in
8
conditions
Dr. Jane Little
Hematology

UNC Physicians Network LLC

1301 Central Dr, 
Sanford, NC 
 (77.6 miles away)
919-718-9512
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jane Little is a Hematologist in Sanford, North Carolina. Dr. Little is highly rated in 8 conditions, according to our data. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
21
conditions
Dr. Maleka Ahmed
Hematology
Expertise in
21
conditions
Dr. Maleka Ahmed
Hematology

Southeastern Regional Medical Center

1200 Pine Run Dr, 
Lumberton, NC 
 (133.7 miles away)
910-671-5730
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Maleka Ahmed is a Hematologist in Lumberton, North Carolina. Dr. Ahmed is highly rated in 21 conditions, according to our data. Her top areas of expertise are Hemangioma Thrombocytopenia Syndrome, Paget Disease of the Breast, Thrombocytopenia, and Angiosarcoma.

Expertise in
39
conditions
Dr. Charles Kuzma
Hematology
Expertise in
39
conditions
Dr. Charles Kuzma
Hematology

Office

220 Page Rd, 
Pinehurst, NC 
 (90.5 miles away)
910-715-3500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Charles Kuzma is a Hematologist in Pinehurst, North Carolina. Dr. Kuzma is highly rated in 39 conditions, according to our data. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Angiosarcoma, Inflammatory Breast Cancer, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Everett Ribakove

How do I make an appointment with Dr. Everett Ribakove?

You can book an appointment with Dr. Everett Ribakove by calling their office at 910-671-5730. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Everett Ribakove a top-rated expert for Chronic Myelomonocytic Leukemia (CMML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Everett Ribakove is classified as an Advanced expert for Chronic Myelomonocytic Leukemia (CMML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Everett Ribakove specialize in?

While Dr. Everett Ribakove is a Hematology, they have specific expertise in Chronic Myelomonocytic Leukemia (CMML), Iron Deficiency Anemia, and Childhood Iron Deficiency Anemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Everett Ribakove accept my insurance?

Dr. Everett Ribakove accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 910-671-5730 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ribakove's expertise for a condition
ConditionClose
      View All 106 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile